Initial dose:

300

mg

Tablet

Orally 

once a day

30

days

Maintenance dose:

150

mg

Tablet

Orally 

once a day

continue until disease progression or severe health side effects

Dose Adjustments

• Mild or moderate impairment: no significant dose adjustment provided • Serious hepatic impairment: Avoid the use of nilutamide • Hepatotoxic during treatment (ALT > 2 x ULN or jaundice): permanently terminate the treatment

Metastatic cancer:

1000

mg

Orally 

once a day

in combination with prednisone 5 mg twice a day.
Or
500 mg orally once a day in combination with methyl prednisone 4 mg twice a day.

Dose Adjustments

Moderate hepatotoxicity: 125 mg once a day
Severe hepatotoxicity: discontinue the treatment

3.75

mg

Intramuscular (IM)

4

weeks

or 11.25 mg shown IM for every 12 weeks, or 22.5 mg given IM for every 24 weeks

Dose Adjustments

Renal Dose Adjustments:
There is no adjustment recommended
Liver Dose Adjustments:
There is no adjustment recommended

200 - 300

mg

Orally 

given in 2 to 3 divided doses in a day.
Or
300 mg IM once a week, reduce the dose to 300 mg once every 2 weeks depending on clinical symptoms.

Dose Adjustments

Meningioma: Terminate the cyproterone administration permanently.
Thrombophlebitis/thromboembolism: Discontinue treatment.
Prostate-specific antigen progression: discontinue cyproterone treatment and monitor for withdrawal symptoms.

Metastatic cancer:

20

mg/m^2

Intravenous (IV)

every 3 weeks

in combination with prednisone 10 mg orally throughout the treatment.

Dose Adjustments

Grade ≥3 diarrhea despite appropriate medication, fluid, and electrolyte replacement: Delay treatment until improvement or resolution, then reduce dose by 1 level.
Grade 2 peripheral neuropathy, delay treatment and reduce dose by 1 level.
Grade >3 peripheral neuropathy Discontinue.

Metastatic/non-metastatic:

250

mg

Orally 

3 times a day

in combination with a luteinizing hormone-releasing agonist

Dose Adjustments

Use of flutamide in severe hepatic impairment is contraindicated.
The use of flutamide is prohibited for patients under dialysis.

Metastatic:

160

mg

orally

once a day

Dose Adjustments

Metastatic/non-metastatic:

240

mg

Tablet

Orally 

once a day

in combination with continuous androgen deprivation therapy

Dose Adjustments

Grade 3 or higher toxicity: Hold the dosing temporarily until symptoms improve to grade 1 or lower and resume the dose with 120 to 180 mg. Cerebrovascular events, grade 3 or 4: discontinue the dosing Dermatologic toxicity: if not managed by oral antihistamines and topical corticosteroids, interrupt or reduce apalutamide dose until symptoms improve Fracture: manage with the use of bone-modifying agents Seizure: discontinue apalutamide dosing permanently Thyroid dysfunction: adjust/ reduce the dose initially, initiate thyroid replacement therapy if indicated

When bicalutamide is combined with an LHRH analog:

50

mg

Orally

once a day

Dose Adjustments

Renal Dose Adjustments
No adjustment required
Liver Dose Adjustments
Caution recommended.

The initial dose was 240 mg as two subcutaneous injections of 120 mg each at a concentration of 40 mg per ml.
80 mg is given as the Maintenance Dose for one subcutaneous injection at a concentration of 20 mg per ml every 28 days
the first maintenance dose should be administered 28 days only after the initial dose

Dose Adjustments

Renal Dose Adjustments:
No adjustment is recommended for mild renal impairment (CrCl 50-80 ml per min)
Use with caution for moderate to severe renal impairment (CrCl <50 ml per min)
Liver Dose Adjustments:
No adjustment is recommended for mild to moderate Hepatic Impairment (Child-Pugh A and B)
Data not available and used with caution for Severe Hepatic Impairment (Child-Pugh C)

Monthly implant: 3.6 mg subcutaneously placed in the upper abdominal wall for every 28days
3-month implant: 10.8 mg subcutaneously placed in the upper abdominal wall for every 12week
Long term treatment intended for unless clinically inappropriate

50 mg implant given SC for every 12 months
The maximum duration of treatment includes removing the implant after 12 months

Dose Adjustments

Renal Impairment:
Dose adjustment not required
Liver impairment:
No data available

55kBq/kg intravenous infusion for 1 minute. Repeat every four weeks for total of 6 weeks

Dose Adjustments

The volume of radium-223 to be administered to a patient should be calculated using the patient's body weight in kilograms, the dosage level of 55 kBq/kg or 1.49 microcurie/kg, the radioactivity concentration of the product at the reference date (1,100 kBq/mL or 30 microcurie/mL), and a decay correction factor to account for the physical decay of the radium-223
The formula for this calculation is (body weight in kg x dosage level) ÷ (decay factor x radioactivity concentration)
The decay correction factor can be found in the prescribing information based on the vial's reference date

Indicated for Metastatic Castration-Resistant Prostate Cancer
300 mg orally twice daily. Continue for a year or until unacceptable toxicity, disease recurrence, or whichever occurs first

rucaparib is a therapeutic agent for the treatment of prostate cancer in men who have been treated with taxane-based chemotherapy and androgen receptor-directed therapy before
A dose of 600 mg is administered orally twice daily
The medication is continued until the disease is reduced to acceptable toxicity
Dose Modifications
In case of adverse reactions, the dose is modified or reduced
The pattern of dose reduction goes like this
First dose reduction: 500 mg daily (two tablets of 250 mg per day)
Second dose reduction: 400 mg daily (two tablets of 200 mg per day)
Third dose reduction: 300 mg daily (one tablet of 300 mg per day)
Hepatic impairment
In case of mild to moderate impairment (total bilirubin <3 x upper limit of normal or AST > upper limit of normal): No dosage modification is recommended
In case of severe impairment (total bilirubin > 3 x upper normal limit and any AST), no studies performed
Renal impairment
In case of mild-to-moderate impairment (when CrCl is 30-89), no dose adjustment is required
In case of severe impairment (when CrCl <30 mL/min) or patients are on dialysis, no studies are performed

12-14 mg/m2 intravenous every 21 days for three weeks when combined with corticosteroids

The drug is indicated for non-operable prostate cancer
1.25-2.5 mg orally every 8 hours

500mg orally twice a day

Indicated in the treatment of Castration-Resistant Prostate Cancer in people who are treated with taxane chemotherapy and androgen receptor pathway inhibition
7.4 GBq intravenously every 6 weeks up to 6 doses or until the disease is progressed

Indicated in the treatment of Castration-Resistant Prostate Cancer in people who are treated with taxane chemotherapy and androgen receptor pathway inhibition
7.4 GBq intravenously every 6 weeks up to 6 doses or until the disease is progressed
Dose Modifications If the treatment gets delayed for more than 4 weeks, discontinue the treatment
Reduce the dose by 20% (up to 5.9GBq) once
In the case of 2nd to 3rd-grade myelosuppression, reduce the dose by 20%
For 3rd-grade myelosuppression, discontinue permanently
In the case of renal and hepatic impairment, no dose adjustment is required

No safe dosing is established

Refer adult dosing

1.25-2.5 mg orally every 8 hours